Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Pat, Dorr"'
Autor:
Charles A, Boucher, Marina R, Bobkova, Chien-Ching, Hung, Rolf, Kaiser, Anne-Geneviève, Marcelin, Adrian, Streinu-Cercel, Jean, van Wyk, Pat, Dorr, Anne-Mieke, Vandamme
Publikováno v:
AIDS reviews. 20(1)
This article is the second of a two-part review aiming to identify gaps in the knowledge and management of human immunodeficiency virus type 1 drug resistance (HIVDR) from global and regional perspectives. Here, we examine the policy and programmatic
Autor:
Charles A, Boucher, Marina R, Bobkova, Anna Maria, Geretti, Chien-Ching, Hung, Rolf, Kaiser, Anne-Geneviève, Marcelin, Adrian, Streinu-Cercel, Jean, van Wyk, Pat, Dorr, Anne-Mieke, Vandamme
Publikováno v:
AIDS reviews. 20(1)
Resistance to antiretroviral therapy (ART) threatens the efficacy of human immunodeficiency virus type 1 (HIV-1) treatment. We present a review of knowledge gaps in the science and technologies of acquired HIV-1 drug resistance (HIVDR) in an effort t
Publikováno v:
Future Virology. 10:949-959
ABSTRACT Aim: We examined the literature for the efficacy, safety and tolerability of lopinavir/ritonavir (LPV/r)-based regimens in antiretroviral therapy naive HIV-1-infected subjects with advanced disease. Materials & methods: Virologic and immunol
Autor:
Graham Rickett, Pat Dorr, Mark Holbrook, Michael Mosley, Harriet Sale, Roy Mansfield, Carolyn Napier
Publikováno v:
Biochemical Pharmacology. 71:163-172
The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel CCR5 antagonists, such as maraviroc (UK-427,857). To do this we cloned and expressed CCR5 from rhesus macaque and compared the bi
Publikováno v:
Clinical Pharmacology & Therapeutics. 78:508-519
Background The viral dynamics of human immunodeficiency virus (HIV) infection has been widely studied and expressed as mathematic equations. For most of the current registered antiretroviral drugs, the pharmacokinetics is well characterized and some
Autor:
Elna van der Ryst, Tim M Jenkins, Maria Conceição do Rosário, Philippe Jacqmin, Pat Dorr, Samantha Abel, Ian James
BACKGROUND Maraviroc, a noncompetitive antagonist of the CCR5 coreceptor, was recently approved in the USA as a treatment of HIV infection. For antiretroviral agents that target the virus, antiviral effect can be related to some extent to plasma drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f07263abdb3233cae03a599bbfc2a49
https://europepmc.org/articles/PMC2311409/
https://europepmc.org/articles/PMC2311409/
Publikováno v:
Biochemical pharmacology. 74(6)
Antagonists of the chemokine receptor, CCR5, may provide important new drugs for the treatment of HIV-1. In this study we have examined the mechanism of action of two functional antagonists of the chemokine receptor CCR5 (UK-396,794, UK-438,235) in s
Publikováno v:
Nation's Restaurant News. 6/26/95, Vol. 29 Issue 26, p42. 1/9p.
Publikováno v:
Journal of Information Systems. Fall2004, Vol. 18 Issue 2, p7-28. 22p. 8 Charts.
Autor:
Jefferson Graham
Publikováno v:
USA Today. 02/17/2006.